These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: A prospective explorative study with a historical control group. Maschio M, Zarabla A, Maialetti A, Fabi A, Vidiri A, Villani V, Giannarelli D. Epilepsy Behav; 2017 Aug; 73():83-89. PubMed ID: 28623754 [Abstract] [Full Text] [Related]
5. Adjunctive lacosamide in clinical practice: sodium blockade with a difference? Stephen LJ, Kelly K, Parker P, Brodie MJ. Epilepsy Behav; 2011 Nov; 22(3):499-504. PubMed ID: 21890421 [Abstract] [Full Text] [Related]
6. Lacosamide tolerability in adult patients with partial-onset seizures: Impact of planned reduction and mechanism of action of concomitant antiepileptic drugs. Foldvary-Schaefer N, Fong JS, Morrison S, Wang L, Bena J. Epilepsy Behav; 2016 Apr; 57(Pt A):155-160. PubMed ID: 26956629 [Abstract] [Full Text] [Related]
8. Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: Analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials. Biton V, Gil-Nagel A, Isojarvi J, Doty P, Hebert D, Fountain NB. Epilepsy Behav; 2015 Nov; 52(Pt A):119-27. PubMed ID: 26414341 [Abstract] [Full Text] [Related]
12. Long-term efficacy and safety of lacosamide monotherapy in the treatment of partial-onset seizures: A multicenter evaluation. Giráldez BG, Toledano R, García-Morales I, Gil-Nagel A, López-González FJ, Tortosa D, Ojeda J, Serratosa JM. Seizure; 2015 Jul; 29():119-22. PubMed ID: 26076854 [Abstract] [Full Text] [Related]
14. Long-term exposure and safety of lacosamide monotherapy for the treatment of partial-onset (focal) seizures: Results from a multicenter, open-label trial. Vossler DG, Wechsler RT, Williams P, Byrnes W, Therriault S, ALEX-MT study group. Epilepsia; 2016 Oct; 57(10):1625-1633. PubMed ID: 27528101 [Abstract] [Full Text] [Related]
15. Lacosamide treatment of childhood refractory focal epilepsy: the first reported side effect in paediatric patients. Yildiz EP, Ozkan MU, Bektas G, Uzunhan TA, Aydinli N, Caliskan M, Ozmen M. Childs Nerv Syst; 2017 Nov; 33(11):2023-2027. PubMed ID: 28884208 [Abstract] [Full Text] [Related]
16. [Lacosamide (vimpat). Prospects for clinical application]. Rudakova IG, Vlasov PN, Lipatova LV, Voronkova KV. Zh Nevrol Psikhiatr Im S S Korsakova; 2017 Nov; 117(9):147-152. PubMed ID: 29053136 [Abstract] [Full Text] [Related]
17. Control of seizures in different stages of partial epilepsy: LACO-EXP, a Spanish retrospective study of lacosamide. Villanueva V, López FJ, Serratosa JM, González-Giraldez B, Campos D, Molins A, Rodriguez Uranga J, Mauri JA, Salas-Puig J, Toledo M, Sánchez-Alvarez JC, Moreno A, Serrano-Castro PJ, Saiz-Diaz RA, González de la Aleja J, de la Peña P, Asensio M. Epilepsy Behav; 2013 Nov; 29(2):349-56. PubMed ID: 23999191 [Abstract] [Full Text] [Related]
18. Lacosamide in the treatment of patients with epilepsy and intellectual disabilities: A long-term study of 136 patients. Böttcher S, Lutz MT, Mayer T. Epilepsia; 2017 Oct; 58(10):1749-1754. PubMed ID: 28804872 [Abstract] [Full Text] [Related]